home / stock / pstv / pstv news

PSTV News and Press, PLUS THERAPEUTICS Inc. From 02/14/23

Stock Information
Company Name: PLUS THERAPEUTICS Inc.
Stock Symbol: PSTV
Market: NYSE
Website: plustherapeutics.com
Menu
PSTV PSTV Quote PSTV Short PSTV News PSTV Articles PSTV Message Board
Get PSTV Alerts

News, Short Squeeze, Breakout and More Instantly...
PSTV - Plus Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023

AUSTIN, Texas, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, announced that the Company will report...
PSTV - Plus Therapeutics Completes Enrollment in Second ReSPECT-LM Phase 1 Trial Cohort of Rhenium (¹??Re) Obisbemeda for the Treatment of Leptomeningeal Metastases

AUSTIN, Texas, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today annou...

PSTV - Plus Therapeutics Announces First Patient Dosed in ReSPECT-GBM Phase 2b Trial of Rhenium (186Re) Obisbemeda for Treatment of Recurrent Glioblastoma

AUSTIN, Texas, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today annou...

PSTV - Plus Therapeutics Provides Updates on ReSPECT(TM) Clinical Trials at the 27th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology

ReSPECT-GBM clinical trial of rhenium ( 186 Re) obisbemeda in recurrent glioblastoma continues to demonstrate safety and overall survival correlates with radiation dose to tumor ReSPECT-GBM Phase 2 trial enrollment has begun Update on ReSPECT-LM clinical tria...
PSTV - Plus Therapeutics to Provide Update on ReSPECT(TM) Clinical Trials at the 27th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology

Recurrent glioblastoma and leptomeningeal metastases data have been selected for oral presentations Pediatric brain cancer plans will be shared via poster session AUSTIN, Texas, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the ...

PSTV - Plus Therapeutics Announces Selection of "Rhenium (186Re) Obisbemeda" as International Non-Proprietary Name for 186RNL

AUSTIN, Texas, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that the World H...

PSTV - Plus Therapeutics Q3 net loss widens Y/Y

Plus Therapeutics ( NASDAQ: PSTV ) stock was largely flat on Friday after the company's Q3 results which saw Q3 GAAP EPS beat estimates. The cancer drugmaker's GAAP net loss was -$5.2M, or -$0.19 per share, compared to a net loss of -$3.7M, or -$0.28 per share in Q3 ...
PSTV - Plus Therapeutics, Inc. (PSTV) Q3 2022 Earnings Call Transcript

Plus Therapeutics, Inc. (PSTV) Q3 2022 Earnings Conference Call October 20, 2022 17:00 ET Corporate Participants Marc Hedrick - President and Chief Executive Officer Norman LaFrance - Chief Medical Officer Andrew Sims - Chief Financial Officer Conference Ca...

PSTV - Plus Therapeutics GAAP EPS of -$0.19 beats by $0.02, revenue of $73K

Plus Therapeutics press release ( NASDAQ: PSTV ): Q3 GAAP EPS of -$0.19 beats by $0.02 . Revenue of $73K. The Company’s cash balance was $20.3 million at September 30, 2022, compared to $18.4 million at December 31, 2021. For further details see: P...

PSTV - Plus Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

Awarded $17.6 million Product Development Research grant by the Cancer Prevention & Research Institute of Texas (CPRIT) to fund 186 RNL development for leptomeningeal metastases (LM) Completed cGMP manufacturing objectives to support Phase 2 clinical trials for ...
Previous 10 Next 10